Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX1739 for Opioid-Induced Respiratory Depression
NCT02735629Phase 2Unknown
- Sponsor
- RespireRx Pharmaceuticals
- Start
- Mar 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CX-1739 in opioid-induced respiratory depression (OIRD), sponsored by RespireRx Pharmaceuticals. Status: unknown.
02
Drugs
CX-1739
03
Conditions
opioid-induced respiratory depression (OIRD)
Beyond the preview
Go deeper on NCT02735629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02735629.